<DOC>
	<DOCNO>NCT02939391</DOCNO>
	<brief_summary>The primary objective evaluate effect KW-6356 motor symptom Parkinson 's disease primary endpoint change baseline MDS-UPDRS part III score KW-6356 placebo subject early Parkinson 's disease Japan .</brief_summary>
	<brief_title>A Study KW-6356 Subjects With Early Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Subject fulfills UK Parkinson 's Disease Society brain bank clinical diagnostic criterion Parkinson 's disease patient Stages 1 3 Modified Hoehn Yahr Scale MDSUPDRS part III score ≥ 15 Use CYP3A4/5related drug within 2 week prior enrollment . Use specify antiparkinsonian drug dopamine antagonist specify period . Treatment levodopa/DCI time past period 4 week . Neurosurgical operation Parkinson 's disease ( stereotactic surgery , deep brain stimulation gamma knife ) , treatment transcranial magnetic stimulation ( TMS ) . Either follow criterion consecutively screen enrollment ; Resting Pulse &gt; 100 bpm Resting systolic blood pressure &gt; 140 mmHg , diastolic blood pressure &gt; 90 mmHg Significant dementia MiniMental State Examination ( MMSE ) score ≤ 23 . Subject history evidence suicidal ideation ( severity 4 5 ) suicidal behavior base assessment ColumbiaSuicide Severity Rating Scale ( CSSRS ) baseline . Anyone otherwise consider unsuitable study investigator subinvestigator include unable communicate cooperate investigator subinvestigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>